MHLW Delays Trabectedin Approval
This article was originally published in PharmAsia News
A working group of Japan's Ministry of Health, Labor and Welfare on unapproved drugs has delayed approving soft tissue sarcoma drug Yondelisa (trabectedin), developed by Spanish pharmaceutical company Zeltia's subsidiary PharmaMar. MHLW cited a lack of testing data and unconfirmed targeting of patients and said it awaits the release of further data. Trabectedin was approved by EMEA last July, and has yet to be approved by FDA
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.